---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-045628"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T15:36:59.142560+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tenaya Therapeutics prices $52.5M public offering of units with warrants

## Summary
- Priced 75M units at $0.70/unit; gross proceeds ~$52.5M before expenses.
- Each unit: one share common + Series A warrant (1 share at $0.80, 5yr) + Series B warrant (0.5 share at $0.70, expires June 30, 2026).
- Offering expected to close March 5, 2025; Leerink Partners and Piper Sandler are joint book-runners.
- Net proceeds to fund development of TN-201 and TN-401, and for working capital.
- Company also terminated ATM prospectus under existing sales agreement with Leerink Partners as of March 3, 2025.

## SEC filing metadata
- accession: 0001193125-25-045628
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000119312525045628/0001193125-25-045628-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000119312525045628/d878268d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-045628
- JSON: https://secwatch.observer/filing/0001193125-25-045628.json
- Plain text: https://secwatch.observer/filing/0001193125-25-045628.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.